On September 16, the news of Ranbaxy receiving the US FDA nod to market an oral suspension drug, Cephalexin, led to a major upswing in the company
Top Section
Explore Business Standard
Top Section
Explore Business Standard
Don’t miss the latest developments in business and finance.
On September 16, the news of Ranbaxy receiving the US FDA nod to market an oral suspension drug, Cephalexin, led to a major upswing in the company
First Published: Sep 17 2003 | 12:00 AM IST